bi-sialidase fusion protein E-602

{
  "id": "MLC-T-ONC-012028",
  "term": "bi-sialidase fusion protein E-602",
  "field": "Oncology and biomedicine",
  "definition": "A fusion protein composed of two engineered human sialidase molecules fused to an Fc antibody domain, with potential immunomodulating and antineoplastic activities. Upon administration, bi-sialidase fusion protein E-602 targets and binds to sialoglycans overexpressed on the cell surface of certain tumor cells and immune cells, such as exhausted T cells. This degrades the immunosuppressive sialoglycans and allows for the re-activation of the immune system, thereby inducing an anti-tumor immune response. Sialidase is an enzymatic degrader of immunosuppressive sialoglycans. E-602 is based on the enzyme-antibody glyco-ligand editing (EAGLE) platform. The Fc domain enhances retention in the tumor, half-life and manufacturability.",
  "synonyms": [
    "EAGLE fusion protein E-602"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bi-sialidase-fusion-protein-e-602/"
}